CD47 and neoplasm: Interestingly, the development of an in situ tumor vaccine expressing anti-CD47 antibodies resulted in tumor growth suppression, stronger long-term survival, and increased tumor-infiltrating lymphocytes in melanoma, lymphoma, and breast cancer mouse models [85].